# Eledon Pharmaceuticals, Inc.: financial statements, quarterly

ELDN · Nasdaq · CIK 1404281 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/eldn.md) · [Financials](/companies/eldn/financials.md) · [Filings](/companies/eldn/filings.md) · [Insiders](/companies/eldn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/eldn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [7.9](/filings/0000950170-24-125622.md) | [7.1 d](/filings/0001193125-25-180865.md) | [7.4](/filings/0001193125-25-180904.md) | [10.1](/filings/0001193125-25-180906.md) | [16.5](/filings/0001193125-25-283275.md) | [17.9 d](/filings/0001193125-26-116164.md) | [13.5](/filings/0001193125-26-221702.md) | [20.3](/filings/0001193125-26-349314.md) | [15.0](/filings/0001193125-25-283275.md) | [17.5 d](/filings/0001193125-26-116164.md) | [17.2](/filings/0001193125-26-221702.md) | [18.2](/filings/0001193125-26-349314.md) |
| Operating income | $m | [(11.2)](/filings/0000950170-24-125622.md) | [(10.3) d](/filings/0000950170-24-038091.md) | [(10.9)](/filings/0001193125-25-180904.md) | [(14.5)](/filings/0001193125-25-180906.md) | [(20.5)](/filings/0001193125-25-283275.md) | not reported | [(18.0)](/filings/0001193125-26-221702.md) | [(24.7)](/filings/0001193125-26-349314.md) | [(19.1)](/filings/0001193125-25-283275.md) | not reported | [(21.2)](/filings/0001193125-26-221702.md) | [(22.9)](/filings/0001193125-26-349314.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(9.9)](/filings/0000950170-24-125622.md) | [(30.1) d](/filings/0001193125-25-180865.md) | [(23.6)](/filings/0001193125-25-283275.md) | [(44.9)](/filings/0001193125-25-283275.md) | [77.0](/filings/0001193125-25-283275.md) | [(44.6) d](/filings/0001193125-26-116164.md) | [(6.5)](/filings/0001193125-26-349314.md) | [(11.2)](/filings/0001193125-26-349314.md) | [(17.5)](/filings/0001193125-25-283275.md) | [(10.4) d](/filings/0001193125-26-116164.md) | [(39.0)](/filings/0001193125-26-349314.md) | [(31.6)](/filings/0001193125-26-349314.md) |
| Diluted EPS | $ per share | [(0.33)](/filings/0000950170-24-125622.md) | not reported | [(0.65)](/filings/0001193125-25-180904.md) | [(0.92)](/filings/0001193125-25-180906.md) | [(0.28)](/filings/0001193125-25-283275.md) | not reported | [(0.08)](/filings/0001193125-26-221702.md) | [(0.13)](/filings/0001193125-26-349314.md) | [(0.21)](/filings/0001193125-25-283275.md) | not reported | [(0.33)](/filings/0001193125-26-221702.md) | [(0.27)](/filings/0001193125-26-349314.md) |
| Basic EPS | $ per share | [(0.33)](/filings/0000950170-24-125622.md) | not reported | [(0.65)](/filings/0001193125-25-180904.md) | [(0.92)](/filings/0001193125-25-180906.md) | [1.05](/filings/0001193125-25-283275.md) | not reported | [(0.08)](/filings/0001193125-26-221702.md) | [(0.13)](/filings/0001193125-26-349314.md) | [(0.21)](/filings/0001193125-25-283275.md) | not reported | [(0.33)](/filings/0001193125-26-221702.md) | [(0.27)](/filings/0001193125-26-349314.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.7](/filings/0000950170-23-062203.md) | [4.6](/filings/0001193125-25-180865.md) | [5.7](/filings/0000950170-24-098582.md) | [26.0](/filings/0000950170-24-098590.md) | [6.8](/filings/0000950170-24-125622.md) | [20.5](/filings/0001193125-26-116164.md) | [8.5](/filings/0001193125-25-180904.md) | [5.7](/filings/0001193125-25-180906.md) | [3.7](/filings/0001193125-25-283275.md) | [22.8](/filings/0001193125-26-349314.md) | [6.2](/filings/0001193125-26-221702.md) | [6.8](/filings/0001193125-26-349314.md) |
| Current assets | $m | [63.0](/filings/0000950170-23-062203.md) | [56.1](/filings/0001193125-25-180865.md) | [48.0](/filings/0000950170-24-098582.md) | [87.2](/filings/0000950170-24-098590.md) | [81.5](/filings/0000950170-24-125622.md) | [144](/filings/0001193125-26-116164.md) | [128](/filings/0001193125-25-180904.md) | [111](/filings/0001193125-25-180906.md) | [96.3](/filings/0001193125-25-283275.md) | [136](/filings/0001193125-26-349314.md) | [114](/filings/0001193125-26-221702.md) | [93.1](/filings/0001193125-26-349314.md) |
| Total assets | $m | [96.1](/filings/0000950170-23-062203.md) | [89.1](/filings/0001193125-25-180865.md) | [80.8](/filings/0000950170-24-098582.md) | [120](/filings/0000950170-24-098590.md) | [115](/filings/0000950170-24-125622.md) | [177](/filings/0001193125-26-116164.md) | [161](/filings/0001193125-25-180904.md) | [145](/filings/0001193125-25-180906.md) | [130](/filings/0001193125-25-283275.md) | [169](/filings/0001193125-26-349314.md) | [147](/filings/0001193125-26-221702.md) | [126](/filings/0001193125-26-349314.md) |
| Current liabilities | $m | [2.9](/filings/0000950170-23-062203.md) | [3.9](/filings/0001193125-25-180865.md) | [4.2](/filings/0000950170-24-098582.md) | [6.0](/filings/0000950170-24-098590.md) | [12.5](/filings/0000950170-24-125622.md) | [11.6](/filings/0001193125-26-116164.md) | [9.2](/filings/0001193125-25-180904.md) | [13.7](/filings/0001193125-25-180906.md) | [14.3](/filings/0001193125-25-283275.md) | [18.3](/filings/0001193125-26-349314.md) | [13.5](/filings/0001193125-26-221702.md) | [11.8](/filings/0001193125-26-349314.md) |
| Total liabilities | $m | [60.5](/filings/0000950170-24-125622.md) | [81.9](/filings/0001193125-25-180865.md) | [95.5](/filings/0000950170-24-098582.md) | [129](/filings/0000950170-24-098590.md) | [38.5](/filings/0000950170-24-125622.md) | [59.3](/filings/0001193125-26-116164.md) | [46.7](/filings/0001193125-25-180904.md) | [38.9](/filings/0001193125-25-180906.md) | [38.8](/filings/0001193125-25-283275.md) | [32.2](/filings/0001193125-26-349314.md) | [46.2](/filings/0001193125-26-221702.md) | [54.1](/filings/0001193125-26-349314.md) |
| Shareholders' equity | $m | [35.6](/filings/0000950170-24-125622.md) | [(48.5)](/filings/0001193125-26-116164.md) | [(70.4)](/filings/0001193125-25-283275.md) | [(64.2)](/filings/0001193125-25-283275.md) | [20.4](/filings/0001193125-25-283275.md) | [62.4](/filings/0001193125-26-349314.md) | [58.9](/filings/0001193125-26-349314.md) | [50.3](/filings/0001193125-26-349314.md) | [35.4](/filings/0001193125-25-283275.md) | [81.1](/filings/0001193125-26-349314.md) | [44.8](/filings/0001193125-26-349314.md) | [33.0](/filings/0001193125-26-349314.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.3) d](/filings/0000950170-24-125622.md) | [(9.1) d](/filings/0001193125-25-180865.md) | [(8.7)](/filings/0001193125-25-180904.md) | [(7.8) d](/filings/0001193125-25-180906.md) | [(11.8) d](/filings/0001193125-25-283275.md) | [(19.0) d](/filings/0001193125-26-116164.md) | [(16.1)](/filings/0001193125-26-221702.md) | [(17.7) d](/filings/0001193125-26-349314.md) | [(14.5) d](/filings/0001193125-25-283275.md) | [(14.1) d](/filings/0001193125-26-116164.md) | [(22.6)](/filings/0001193125-26-221702.md) | [(22.7) d](/filings/0001193125-26-349314.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.3](/filings/0000950170-23-062203.md) | [14.3](/filings/0000950170-24-098582.md) | [24.0](/filings/0000950170-24-098590.md) | [30.0](/filings/0000950170-24-125622.md) | [30.0](/filings/0001193125-25-180904.md) | [42.3](/filings/0001193125-25-180906.md) | [55.5](/filings/0001193125-25-283275.md) | [77.1](/filings/0001193125-26-221702.md) | [77.2](/filings/0001193125-26-349314.md) | [77.2](/filings/0001193125-25-283275.md) | [112](/filings/0001193125-26-221702.md) | [114](/filings/0001193125-26-349314.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 81,261,152 at 2026-08-10, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349314.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.